ArticleRadiology2016
CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.Seminars in cancer biology · 2022Pooled it
- The application of radiomics in laryngeal cancer.The British journal of radiology · 2021Pooled it
- CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.AJR. American journal of roentgenology · 2019Pooled it
- CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.International journal of clinical oncology · 2019Pooled it
- Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management.Journal of neuro-oncology · 2026Article
- Multimodal Artificial Intelligence in Lung Cancer: From Data Integration to Precision Oncology.Cancers · 2026Review
- Quantitative PCCT spectral parameters for noninvasive prediction of EGFR status and its subtypes in lung adenocarcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- The clinicoradiological and pathological-molecular characteristics associated with spread through air spaces in stage IA invasive lung adenocarcinoma.Insights into imaging · 2026Article
- Advances in Multi-Modal Biomarkers for Immunotherapy Response in Non-Small Cell Lung Cancer: ctDNA, Microbiome, and Radiomics.Cancers · 2026Review
- Review
- Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.Journal of thoracic disease · 2025Article
- Imaging appearances, CT evolution patterns, and surgical prognosis of stage I lung squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Nomogram to predict the EGFR mutation status in stage III-IV solid lung adenocarcinoma patients.BMC medical imaging · 2025Article
- Oncogene-driven lung cancer in the era of radiogenomics: current evidence and future developments.Discover oncology · 2025Review
- An online explainable ensemble machine learning model for predicting epidermal growth factor receptor mutation status in lung adenocarcinoma.Translational lung cancer research · 2025Article
- Predicting abnormal epicardial adipose tissue in psoriasis patients by integrating radiomics from non-contrast chest CT with serological biomarkers.BMC medical imaging · 2025Article
- Radiomics based on preoperative magnetic resonance imaging predict the cell lineages of nonfunctioning pituitary neuroendocrine tumors.Neuroradiology · 2025Article
- Roles of artificial intelligence and high frame-rate contrast-enhanced ultrasound in the differential diagnosis of Breast Imaging Reporting and Data System 4 breast nodules.Gland surgery · 2025Article
- Article
- Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma.Frontiers in oncology · 2025Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose To retrospectively identify the relationship between epidermal growth factor receptor (EGFR) mutation status, predominant histologic subtype, and computed tomographic (CT) characteristics in surgically resected lung adenocarcinomas in a cohort of Asian patients. materials and Methods This study was approved by the institutional review board, with waiver of informed consent. Preoperative chest CT findings were retrospectively evaluated in 385 surgically resected lung adenocarcinomas. A total of 30 CT descriptors were assessed. EGFR mutations at exons 18-21 were determined by using the amplification refractory mutation system. Multiple logistic regression analyses were performed to identify independent factors of harboring EGFR mutation status. The final model was selected by using the backward elimination method, and two areas under the receiver operating characteristic curve (ROC) were compared with the nonparametric approach of DeLong, DeLong, and Clarke-Pearson. Results EGFR mutations were found in 168 (43.6%) of 385 patients. Mutations were found more frequently in (a) female patients (P < .001); (b)those who had never smoked (P < .001); (c)those with lepidic predominant adenocarcinomas (P = .001) or intermediate pathologic grade (P < .001); (e) smaller tumors (P < .001); (f)tumors with spiculation (P = .019), ground-glass opacity (GGO) or mixed GGO (P < .001), air bronchogram (P = .006), bubblelike lucency (P < .001), vascular convergence (P = .024), thickened adjacent bronchovascular bundles (P = .027), or pleural retraction (P < .001); and (g) tumors without pleural attachment (P = .004), a well-defined margin (P = .010), marked heterogeneous enhancement (P = .001), severe peripheral emphysema (P = .002), severe peripheral fibrosis (P = .013), or lymphadenopathy (P = .028). The most important and significantly independent prognostic factors of harboring EGFR-activating mutation for the model with both clinical variables and CT features were those who had never smoked and those with smaller tumors, bubblelike lucency, homogeneous enhancement, or pleural retraction when adjusting for histologic subtype, pathologic grade, or thickened adjacent bronchovascular bundles. ROC curve analysis showed that use of clinical variables combined with CT features (area under the ROC curve = 0.778) was superior to use of clinical variables alone (area under the ROC curve = 0.690). Conclusion CT imaging features of lung adenocarcinomas in combination with clinical variables can be used to prognosticate EGFR mutation status better than use of clinical variables alone. (©) RSNA, 2016 Online supplemental material is available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.